Kura Oncology (NASDAQ:KURA) Earns Market Outperform Rating from JMP Securities

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating reaffirmed by equities research analysts at JMP Securities in a research note issued on Monday, Benzinga reports. They currently have a $32.00 price target on the stock. JMP Securities’ price objective would suggest a potential upside of 51.87% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a report on Friday, May 3rd. Wedbush restated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, May 3rd. Finally, StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $28.28.

Kura Oncology Stock Up 0.3 %

KURA stock opened at $21.07 on Monday. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -9.71 and a beta of 0.89. The business’s fifty day moving average price is $20.65 and its two-hundred day moving average price is $16.22. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.67 and a quick ratio of 16.67.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.50) earnings per share. On average, equities analysts anticipate that Kura Oncology will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

Institutional investors have recently bought and sold shares of the stock. Deerfield Management Company L.P. Series C boosted its holdings in Kura Oncology by 35.1% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after acquiring an additional 1,136,044 shares during the last quarter. BVF Inc. IL grew its holdings in shares of Kura Oncology by 9.5% in the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after acquiring an additional 642,245 shares in the last quarter. Verition Fund Management LLC bought a new stake in Kura Oncology during the fourth quarter worth $6,695,000. Vanguard Group Inc. grew its stake in Kura Oncology by 7.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,924,448 shares of the company’s stock valued at $35,791,000 after purchasing an additional 275,173 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Kura Oncology by 10.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock worth $28,785,000 after purchasing an additional 197,530 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.